Everest Medicines Ltd
01952
Company Profile
Business description
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.
Contact
1168 West Nanjing Road
16th Floor, CITIC Pacific Plaza
Jing’an District
Shanghai200041
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
722
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
Shares screen as undervalued after prolonged decline.
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 65.20 | 0.72% |
| CAC 40 | 8,323.28 | 49.44 | 0.60% |
| DAX 40 | 25,014.87 | 293.41 | 1.19% |
| Dow JONES (US) | 50,122.26 | 6.59 | 0.01% |
| FTSE 100 | 10,386.23 | 16.48 | 0.16% |
| HKSE | 27,027.16 | 467.21 | 1.76% |
| NASDAQ | 23,260.33 | 229.12 | 0.99% |
| Nikkei 225 | 56,363.94 | 2,110.26 | 3.89% |
| NZX 50 Index | 13,446.37 | 2.35 | 0.02% |
| S&P 500 | 6,969.96 | 37.66 | 0.54% |
| S&P/ASX 200 | 8,870.10 | 59.20 | 0.67% |
| SSE Composite Index | 4,123.09 | 57.51 | 1.41% |